Senti Biosciences, Inc. (SNTI)

Over the past six months, Senti Biosciences' stock price has experienced significant volatility and a notable decline. The stock decreased from $4.36 per share on January 31, 2025, to $1.00 per share by January 30, 2026, representing a 77.06% decrease. Key events include a 1-for-10 reverse stock split on July 18, 2024, and the appointment of Bryan Baum to the Board of Directors on July 18, 2025. Analyst coverage was initiated by HC Wainwright & Co. and Leerink Partners with positive recommendations. The company reported its Q3 2025 financial results on November 13, 2025, missing analysts' consensus estimates for earnings per share. Positive data from the Phase 1 trial of SENTI-202 and its FDA RMAT designation were announced in December 2025. The stock price reached new 52-week lows in January 2026. Senti Biosciences was selected for an on-stage presentation at the Healthcare Conference Taipei 2026.

Specific information regarding demand seasonality for Senti Biosciences, Inc.'s products and services is not explicitly detailed. Demand for its potential future products would likely be driven by medical need and clinical efficacy rather than traditional seasonal consumer patterns.

Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies, operating within the Health Technology sector and Biotechnology industry. The company uses a synthetic biology platform to engineer gene circuits into new medicines, designed to precisely target and kill cancer cells, spare healthy cells, increase specificity to target tissues, and control drug expression. Its product candidates include SENTI-202 for blood cancers and SENTI-301A for GPC3 positive tumors, along with preclinical and partnered programs.

Senti Biosciences, Inc. is headquartered in South San Francisco, California.

Senti Biosciences' brand reputation has been influenced by positive clinical trial results for SENTI-202 and its FDA RMAT designation. Analyst endorsements from firms like HC Wainwright & Co. and Leerink Partners have also contributed positively. However, the company has faced scrutiny amid critical trial halts, which could have negatively impacted its reputation.

Senti Biosciences, Inc. has a diverse ownership structure, with institutional shareholders owning 22.30% of the stock, insiders holding 97.70%, and retail investors holding 0.00%. Major institutional owners include NEA Management Company, LLC, and Vanguard Group Inc. Significant individual/insider owners include Celadon Partners Spv 24 and Omid Farokhzad.